142 related articles for article (PubMed ID: 29710433)
1. Remnant vital tissue following locoregional therapy for hepatocellular carcinoma: another player in the game.
Rubin A; Berenguer M
Transpl Int; 2018 Apr; ():. PubMed ID: 29710433
[TBL] [Abstract][Full Text] [Related]
2. Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients, a multicentre cohort study.
Manzia TM; Lai Q; Iesari S; Perera MTPR; Komuta M; Carvalheiro A; Shah T; Angelico R; Quaranta C; Nicolini D; Montalti R; Scarpelli M; Palmieri G; Orlacchio A; Vivarelli M; Angelico M; Lerut J; Tisone G
Transpl Int; 2018 Mar; ():. PubMed ID: 29572974
[TBL] [Abstract][Full Text] [Related]
3. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.
Rich NE; Parikh ND; Singal AG
Curr Treat Options Gastroenterol; 2017 Jun; 15(2):296-304. PubMed ID: 28425018
[TBL] [Abstract][Full Text] [Related]
5. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
6. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
Degroote H; PiƱero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria.
Elshamy M; Aucejo F; Menon KV; Eghtesad B
World J Hepatol; 2016 Jul; 8(21):874-80. PubMed ID: 27478537
[TBL] [Abstract][Full Text] [Related]
8. Liver transplantation and hepatocellular carcinoma 2023: a narrative review of management and outcomes.
Tabrizian P; Holzner ML; Zaret D; Meyerovich G; Fagenson A; Schiano T
Ann Palliat Med; 2024 Jan; 13(1):126-140. PubMed ID: 38124475
[TBL] [Abstract][Full Text] [Related]
9. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
[TBL] [Abstract][Full Text] [Related]
10. Pre-Transplant Factors Influencing Rates of Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients.
Zucker KM; Gomez PA; Kezirian O; Mehta S
Gastroenterology Res; 2021 Jun; 14(3):190-193. PubMed ID: 34267835
[TBL] [Abstract][Full Text] [Related]
11. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.
DiNorcia J; Florman SS; Haydel B; Tabrizian P; Ruiz RM; Klintmalm GB; Senguttuvan S; Lee DD; Taner CB; Verna EC; Halazun KJ; Hoteit M; Levine MH; Chapman WC; Vachharajani N; Aucejo F; Nguyen MH; Melcher ML; Tevar AD; Humar A; Mobley C; Ghobrial M; Nydam TL; Amundsen B; Markmann JF; Berumen J; Hemming AW; Langnas AN; Carney CA; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Ann Surg; 2020 Apr; 271(4):616-624. PubMed ID: 30870180
[TBL] [Abstract][Full Text] [Related]
12. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.
El-Gazzaz G; Sourianarayanane A; Menon KV; Sanabria J; Hashimoto K; Quintini C; Kelly D; Eghtesad B; Miller C; Fung J; Aucejo F
Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):34-41. PubMed ID: 23392796
[TBL] [Abstract][Full Text] [Related]
13. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
14. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
[TBL] [Abstract][Full Text] [Related]
15. Predictors of intermediate-term survival with destination locoregional therapy of hepatocellular cancer in patients either ineligible or unwilling for liver transplantation.
Ramanathan M; Shroads M; Choi M; Wood D; Seetharam A
J Gastrointest Oncol; 2017 Oct; 8(5):885-889. PubMed ID: 29184693
[TBL] [Abstract][Full Text] [Related]
16. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
Lee DD; Samoylova M; Mehta N; Musto KR; Roberts JP; Yao FY; Harnois DM
Liver Transpl; 2019 Feb; 25(2):228-241. PubMed ID: 30198150
[TBL] [Abstract][Full Text] [Related]
17. Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same?
Coletta M; Nicolini D; Benedetti Cacciaguerra A; Mazzocato S; Rossi R; Vivarelli M
Transl Gastroenterol Hepatol; 2017; 2():78. PubMed ID: 29034351
[TBL] [Abstract][Full Text] [Related]
18. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
Kwong AJ; Ghaziani TT; Yao F; Sze D; Mannalithara A; Mehta N
Clin Gastroenterol Hepatol; 2022 May; 20(5):1142-1150.e4. PubMed ID: 34358718
[TBL] [Abstract][Full Text] [Related]
19. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
20. Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma.
Sposito C; Cucchetti A; Mazzaferro V
Dig Dis Sci; 2019 Apr; 64(4):1001-1007. PubMed ID: 30852770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]